Business Context and Reporting Period
This Form 6-K filing by Regencell Bioscience Holdings Limited covers the month of February 2026, with the report dated February 13, 2026. The company is a foreign private issuer headquartered in Hong Kong.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity restrictions rather than financial performance.
Material Changes
The primary material change is the extension of lock-up undertakings for directors and employees:
- Extension Period: An additional 12-month lock-up period has been agreed upon, extending until April 20, 2027.
- Employee Coverage: 100% of shares and vested share options held by employees are subject to the lock-up.
- Director Coverage: Between 82% and 92% of shares and vested share options held by directors are subject to the lock-up.
- Previous Status: Prior undertakings were set to expire on April 20, 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies are disclosed in this text, other than the voluntary restriction on share liquidity for insiders.
Investor Verification Checklist
- Verify the specific percentage of director shares locked up (ranging from 82% to 92%) for individual directors.
- Confirm the exact expiration date of the new lock-up (April 20, 2027).
- Review the attached Exhibit 99.1 for the full legal terms of the lock-up undertaking.
- Check subsequent filings for any financial updates, as this 6-K contains no financial data.